Apotea Past Earnings Performance
Past criteria checks 3/6
Apotea has been growing earnings at an average annual rate of 28.3%, while the Consumer Retailing industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 9.1% per year. Apotea's return on equity is 24.8%, and it has net margins of 3.2%.
Key information
28.26%
Earnings growth rate
19.70%
EPS growth rate
| Consumer Retailing Industry Growth | 12.41% |
| Revenue growth rate | 9.09% |
| Return on equity | 24.76% |
| Net Margin | 3.20% |
| Next Earnings Update | 17 Jul 2026 |
Recent past performance updates
Recent updates
Rising Online Pharmacy Demand And New Warehouse Capacity Will Support Long Term Earnings
Catalysts About Apotea Apotea operates a Swedish online pharmacy platform that sells prescription medicines, OTC products and traded goods. What are the underlying business or industry changes driving this perspective?What You Can Learn From Apotea AB (publ)'s (STO:APOTEA) P/S After Its 28% Share Price Crash
The Apotea AB (publ) ( STO:APOTEA ) share price has fared very poorly over the last month, falling by a substantial...Why We Like The Returns At Apotea (STO:APOTEA)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...Apotea AB (publ) (STO:APOTEA) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights Apotea's estimated fair value is kr174 based on 2 Stage Free Cash Flow to Equity Apotea is estimated to be...Apotea is poised for growth with its online pharmacy dominance and upcoming market expansions
Online Pharmacy Market Growth: The Swedish pharmacy market is shifting online, benefiting Apotea as the dominant e-commerce player. Consumers increasingly prefer digital purchases over physical storeRevenue & Expenses Breakdown
How Apotea makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 7,389 | 236 | 985 | 0 |
| 31 Dec 25 | 7,205 | 229 | 956 | 0 |
| 30 Sep 25 | 7,082 | 263 | 957 | 0 |
| 30 Jun 25 | 6,938 | 249 | 933 | 0 |
| 31 Mar 25 | 6,773 | 238 | 906 | 0 |
| 31 Dec 24 | 6,541 | 215 | 876 | 0 |
| 30 Sep 24 | 6,309 | 192 | 840 | 0 |
| 31 Dec 23 | 5,455 | 87 | 744 | 0 |
| 31 Dec 22 | 4,883 | 20 | 712 | 0 |
| 31 Dec 21 | 4,580 | 105 | 602 | 0 |
Quality Earnings: APOTEA has high quality earnings.
Growing Profit Margin: APOTEA's current net profit margins (3.2%) are lower than last year (3.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APOTEA's earnings have grown significantly by 28.3% per year over the past 5 years.
Accelerating Growth: APOTEA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: APOTEA had negative earnings growth (-0.6%) over the past year, making it difficult to compare to the Consumer Retailing industry average (3.9%).
Return on Equity
High ROE: APOTEA's Return on Equity (24.8%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 06:15 |
| End of Day Share Price | 2026/06/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Apotea AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Niklas Ekman | DNB Carnegie |